9.51

5.00% -0.50

Pre-market: 9.53 0.02 +0.21%

Recursion Pharmaceuticals Inc (RXRX)

Overview News Price History Option Chain Financials Why RXRX Down? Discussions Forecast

Recursion Pharmaceuticals Inc stock is currently priced at $9.51, with a 24-hour trading volume of 4.84M. It has seen a -5.00% decreased in the last 24 hours and a +25.63% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $10.12 pivot point. If it approaches the $9.13 support level, significant changes may occur.

Previous Close:

$10.01

Open:

$10.05

24h Volume:

4.84M

Market Cap:

$2.26B

Revenue:

$43.88M

Net Income/Loss:

$-328.07M

P/E Ratio:

-6.8913

EPS:

-1.38

Net Cash Flow:

$-300.33M

1W Performance:

+10.07%

1M Performance:

+25.63%

6M Performance:

+42.58%

1Y Performance:

+85.38%

1D Range:

$9.43

$10.11

52W Range:

$4.97

$16.75

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name

Recursion Pharmaceuticals Inc

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

385 269 0203

Address

41 South Rio Grande Street, Salt Lake City

Employee

218

Twitter

Next Earnings Date

2024-06-03

Latest SEC Filings

RXRX's Discussions on Twitter

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight
Mar-16-23	Initiated	Needham	Buy
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-21	Initiated	Berenberg	Buy
May-11-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Goldman	Neutral
May-11-21	Initiated	JP Morgan	Neutral
May-11-21	Initiated	KeyBanc Capital Markets	Overweight
May-11-21	Initiated	SVB Leerink	Outperform

View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.4% - MarketBeat

MarketBeat

Recursion Pharmaceuticals director sells shares worth over $200k - Investing.com

Investing.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World

Defense World

Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data

Recursion Pharmaceuticals Inc (RXRX) Revenue 2024

RXRX reported a revenue (TTM) of $43.88 million for the quarter ending December 31, 2023, a +10.57% rise year-over-year.

Recursion Pharmaceuticals Inc (RXRX) Net Income 2024

RXRX net income (TTM) was -$328.07 million for the quarter ending December 31, 2023, a -36.99% decrease year-over-year.

Recursion Pharmaceuticals Inc (RXRX) Cash Flow 2024

RXRX recorded a free cash flow (TTM) of -$300.33 million for the quarter ending December 31, 2023, a -148.45% decrease year-over-year.

Recursion Pharmaceuticals Inc (RXRX) Earnings per Share 2024

RXRX earnings per share (TTM) was -$1.57 for the quarter ending December 31, 2023, a -14.60% decline year-over-year.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.